Intravenous golimumab in a dosage of 2 mg/kg, initially given every 4 weeks but then every 8 weeks, in addition to methotrexate, is effective in the treatment of patients with rheumatoid arthritis. This weight-based infusion is administered over thirty minutes with an acceptable safety profile. Since it is a relatively new formulation, more time will be required to assess its specific role in the rheumatologists’ armamentarium and to appreciate more fully its long-term safety.


    Access

    Check access

    Check availability in my library

    Order at Subito €


    Export, share and cite



    Title :

    Intravenous golimumab in rheumatoid arthritis


    Contributors:

    Published in:

    Publication date :

    2014-07-01


    Size :

    8 pages




    Type of media :

    Article (Journal)


    Type of material :

    Electronic Resource


    Language :

    English




    Gouty arthritis masquerading as rheumatoid arthritis or vice versa

    M.D. Talbott, John H. / M.D. Altman, Roy D. / M.D. Yu, Ts'ai-Fan | Elsevier | 1978


    New Therapeutic Approaches for Rheumatoid Arthritis

    Chen, Q. / Wei, W. | British Library Online Contents | 2005


    Muehrcke Lines Associated to Active Rheumatoid Arthritis

    Chavez-Lopez, M.A. / Arce-Martinez, F.J. / Tello-Esparza, A. | British Library Online Contents | 2013


    A Case of Methimazole-Induced Chronic Arthritis Masquerading as Seronegative Rheumatoid Arthritis

    Gruber, C.N. / Finzel, K. / Gruber, B.L. | British Library Online Contents | 2014


    Tuberculous Peritonitis in a Patient With Rheumatoid Arthritis

    Kagohashi, K. / Ohara, G. / Kurishima, K. et al. | British Library Online Contents | 2014